1. Metabolic Enzyme/Protease Anti-infection Apoptosis Immunology/Inflammation NF-κB
  2. Tyrosinase Fungal SARS-CoV Apoptosis Reactive Oxygen Species (ROS)
  3. Retusin

Retusin  (Synonyms: Quercetin-​3,​3',​4',​7-​tetramethylether)

Cat. No.: HY-N6829 Purity: 99.30%
Handling Instructions Technical Support

Retusin (Quercetin-3,3',4',7-tetramethylether) is a tyrosinase inhibitor, with IC50 values of 50.9 μM and 51.8 μM against mushroom and intracellular tyrosinase, respectively. Retusin also acts as a free radical scavenger, melanogenesis inhibitor, anti-apoptosis agent, neuroprotective agent, antiemetic, antifungal agent, and antiviral agent. Retusin scavenges ABTS•+ and DPPH• free radicals. Retusin can be used in studies related to hyperpigmentation, vomiting, Aspergillus niger infection, and COVID-19 infection.

For research use only. We do not sell to patients.

Retusin

Retusin Chemical Structure

CAS No. : 1245-15-4

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of Retusin:

Top Publications Citing Use of Products
  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Retusin (Quercetin-3,3',4',7-tetramethylether) is a tyrosinase inhibitor, with IC50 values of 50.9 μM and 51.8 μM against mushroom and intracellular tyrosinase, respectively. Retusin also acts as a free radical scavenger, melanogenesis inhibitor, anti-apoptosis agent, neuroprotective agent, antiemetic, antifungal agent, and antiviral agent. Retusin scavenges ABTS•+ and DPPH• free radicals. Retusin can be used in studies related to hyperpigmentation, vomiting, Aspergillus niger infection, and COVID-19 infection[1][2][3][4][5].

Cellular Effect
Cell Line Type Value Description References
2008 IC50
50 3
Compound: 17
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
[PMID: 21354800]
2008 IC50
>100 3
Compound: 3, Pque
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
2008 IC50
> 100 3
Compound: 3, Pque
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
2008 IC50
50 3
Compound: 17
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
[PMID: 21354800]
2008 IC50
50 3
Compound: 17
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
Inhibition of MRP1 expressed in human 2008 cells assessed as calcein AM accumulation by cell based assay
[PMID: 21354800]
2008 IC50
> 100 3
Compound: 3, Pque
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human 2008 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A2780 ADR IC50
12 3
Compound: 17
Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay
Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay
[PMID: 21354800]
A2780 ADR IC50
12 3
Compound: 17
Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay
Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay
[PMID: 21354800]
A-375 IC50
69.72 3
Compound: 3, Pque
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-375 IC50
69.72 3
Compound: 3, Pque
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-431 IC50
82.25 3
Compound: 3, Pque
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-431 IC50
57.54 3
Compound: 3, Pque
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-431 IC50
57.54 3
Compound: 3, Pque
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-431 IC50
82.25 3
Compound: 3, Pque
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A549 IC50
>50 3
Compound: 7a
Anticancer activity against human A549 cells by HTS assay
Anticancer activity against human A549 cells by HTS assay
[PMID: 25139569]
A-375 IC50
69.72 3
Compound: 3, Pque
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A375 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A549 IC50
> 50 3
Compound: 7a
Anticancer activity against human A549 cells by HTS assay
Anticancer activity against human A549 cells by HTS assay
[PMID: 25139569]
BXPC-3 IC50
>100 3
Compound: 3, Pque
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-431 IC50
57.54 3
Compound: 3, Pque
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
BXPC-3 IC50
> 100 3
Compound: 3, Pque
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
C13 IC50
> 100 3
Compound: 3, Pque
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
C13 IC50
>100 3
Compound: 3, Pque
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A-431 IC50
82.25 3
Compound: 3, Pque
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against cisplatin-resistant human A431 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
Calu-1 IC50
6.53 3
Compound: 7a
Anticancer activity against human Calu1 cells by HTS assay
Anticancer activity against human Calu1 cells by HTS assay
[PMID: 25139569]
A2780 ADR IC50
12 3
Compound: 17
Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay
Inhibition of P-gp expressed in A2780adr cells by calcein AM accumulation assay
[PMID: 21354800]
Calu-1 IC50
6.53 3
Compound: 7a
Anticancer activity against human Calu1 cells by HTS assay
Anticancer activity against human Calu1 cells by HTS assay
[PMID: 25139569]
HCT-15 IC50
68.11 3
Compound: 3, Pque
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
HCT-15 IC50
68.11 3
Compound: 3, Pque
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
A549 IC50
> 50 3
Compound: 7a
Anticancer activity against human A549 cells by HTS assay
Anticancer activity against human A549 cells by HTS assay
[PMID: 25139569]
HEK293 IC50
141.87 3
Compound: 3, Pque
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
BXPC-3 IC50
> 100 3
Compound: 3, Pque
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human BxPC3 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
HEK293 IC50
141.87 3
Compound: 3, Pque
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
C13 IC50
> 100 3
Compound: 3, Pque
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human C13 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
HeLa IC50
46.37 3
Compound: 7a
Anticancer activity against human HeLa cells by HTS assay
Anticancer activity against human HeLa cells by HTS assay
[PMID: 25139569]
HeLa IC50
46.37 3
Compound: 7a
Anticancer activity against human HeLa cells by HTS assay
Anticancer activity against human HeLa cells by HTS assay
[PMID: 25139569]
HL-60 IC50
28 3
Compound: 19
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
[PMID: 25014747]
HL-60 IC50
28 3
Compound: 19
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
[PMID: 25014747]
Calu-1 IC50
6.53 3
Compound: 7a
Anticancer activity against human Calu1 cells by HTS assay
Anticancer activity against human Calu1 cells by HTS assay
[PMID: 25139569]
HOP-62 IC50
> 50 3
Compound: 7a
Anticancer activity against human HOP62 cells by HTS assay
Anticancer activity against human HOP62 cells by HTS assay
[PMID: 25139569]
HOP-62 IC50
>50 3
Compound: 7a
Anticancer activity against human HOP62 cells by HTS assay
Anticancer activity against human HOP62 cells by HTS assay
[PMID: 25139569]
HCT-15 IC50
68.11 3
Compound: 3, Pque
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human HCT15 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
KB ED50
> 25 6
Compound: retusin
Cytotoxicity against human KB cells after 72 hrs
Cytotoxicity against human KB cells after 72 hrs
[PMID: 1955888]
HEK293 IC50
141.87 3
Compound: 3, Pque
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against HEK293 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
KB ED50
41 6
Compound: NSC-61837
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
[PMID: 469554]
L929 IC50
> 100 3
Compound: 9, 3,7,3',4'-tetra-O-methylated quercetin
Cytotoxicity against mouse L929 cells after 5 days by MTS assay
Cytotoxicity against mouse L929 cells after 5 days by MTS assay
[PMID: 22743241]
KB ED50
>25 6
Compound: retusin
Cytotoxicity against human KB cells after 72 hrs
Cytotoxicity against human KB cells after 72 hrs
[PMID: 1955888]
HL-60 IC50
28 3
Compound: 19
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells after 72 hrs by MTT assay
[PMID: 25014747]
L929 IC50
>100 3
Compound: 9, 3,7,3',4'-tetra-O-methylated quercetin
Cytotoxicity against mouse L929 cells after 5 days by MTS assay
Cytotoxicity against mouse L929 cells after 5 days by MTS assay
[PMID: 22743241]
HOP-62 IC50
> 50 3
Compound: 7a
Anticancer activity against human HOP62 cells by HTS assay
Anticancer activity against human HOP62 cells by HTS assay
[PMID: 25139569]
LOX IMVI IC50
0.39 3
Compound: 7a
Anticancer activity against human LOXIMVI cells by HTS assay
Anticancer activity against human LOXIMVI cells by HTS assay
[PMID: 25139569]
LOX IMVI IC50
0.39 3
Compound: 7a
Anticancer activity against human LOXIMVI cells by HTS assay
Anticancer activity against human LOXIMVI cells by HTS assay
[PMID: 25139569]
HeLa IC50
46.37 3
Compound: 7a
Anticancer activity against human HeLa cells by HTS assay
Anticancer activity against human HeLa cells by HTS assay
[PMID: 25139569]
M14 IC50
0.38 3
Compound: 7a
Anticancer activity against human M14 cells by HTS assay
Anticancer activity against human M14 cells by HTS assay
[PMID: 25139569]
MCF7 IC50
> 100 3
Compound: 3, Pque
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
M14 IC50
0.38 3
Compound: 7a
Anticancer activity against human M14 cells by HTS assay
Anticancer activity against human M14 cells by HTS assay
[PMID: 25139569]
KB ED50
41 6
Compound: NSC-61837
Cytotoxicity against human KB cells
Cytotoxicity against human KB cells
[PMID: 469554]
MCF7 IC50
0.9 3
Compound: 17
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
[PMID: 21354800]
MCF7 IC50
>100 3
Compound: 3, Pque
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
KB ED50
> 25 6
Compound: retusin
Cytotoxicity against human KB cells after 72 hrs
Cytotoxicity against human KB cells after 72 hrs
[PMID: 1955888]
MDCK IC50
0.39 3
Compound: 17
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
[PMID: 21354800]
MCF7 IC50
0.9 3
Compound: 17
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
[PMID: 21354800]
L929 IC50
> 100 3
Compound: 9, 3,7,3',4'-tetra-O-methylated quercetin
Cytotoxicity against mouse L929 cells after 5 days by MTS assay
Cytotoxicity against mouse L929 cells after 5 days by MTS assay
[PMID: 22743241]
MDCK IC50
16 3
Compound: 17
Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry
Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry
[PMID: 21354800]
MDCK IC50
0.39 3
Compound: 17
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
[PMID: 21354800]
LOX IMVI IC50
0.39 3
Compound: 7a
Anticancer activity against human LOXIMVI cells by HTS assay
Anticancer activity against human LOXIMVI cells by HTS assay
[PMID: 25139569]
MDCK-II IC50
0.54 3
Compound: 12
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay
[PMID: 23851114]
MDCK IC50
16 3
Compound: 17
Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry
Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry
[PMID: 21354800]
M14 IC50
0.38 3
Compound: 7a
Anticancer activity against human M14 cells by HTS assay
Anticancer activity against human M14 cells by HTS assay
[PMID: 25139569]
MDCK-II IC50
0.57 3
Compound: 12
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry
[PMID: 23851114]
MDCK-II IC50
0.54 3
Compound: 12
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay
[PMID: 23851114]
MCF7 IC50
0.9 3
Compound: 17
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MCF-7 MX cells using Hoechst 33342 staining
[PMID: 21354800]
NCI/ADR-RES IC50
> 100 3
Compound: 3, Pque
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
MDCK-II IC50
0.57 3
Compound: 12
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry
[PMID: 23851114]
MCF7 IC50
> 100 3
Compound: 3, Pque
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
NCI/ADR-RES IC50
>100 3
Compound: 3, Pque
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
MDCK IC50
0.39 3
Compound: 17
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
Inhibition of BCRP expressed in MDCK cells using Hoechst 33342 staining
[PMID: 21354800]
NCI-H1299 IC50
10.46 3
Compound: 7a
Anticancer activity against human H1299 cells by HTS assay
Anticancer activity against human H1299 cells by HTS assay
[PMID: 25139569]
NCI-H1299 IC50
10.46 3
Compound: 7a
Anticancer activity against human H1299 cells by HTS assay
Anticancer activity against human H1299 cells by HTS assay
[PMID: 25139569]
MDCK IC50
16 3
Compound: 17
Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry
Inhibition of MDR1 expressed in MDCK cells using rhodamine 123 staining by flow cytometry
[PMID: 21354800]
NCI-H157 IC50
> 50 3
Compound: 7a
Anticancer activity against human NCI-H157 cells by HTS assay
Anticancer activity against human NCI-H157 cells by HTS assay
[PMID: 25139569]
NCI-H157 IC50
>50 3
Compound: 7a
Anticancer activity against human NCI-H157 cells by HTS assay
Anticancer activity against human NCI-H157 cells by HTS assay
[PMID: 25139569]
MDCK-II IC50
0.54 3
Compound: 12
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of Hoechst 33342 preincubated for 30 mins before Hoechst 33342 addition measured after 120 mins by fluorescence assay
[PMID: 23851114]
NCI-H1792 IC50
> 50 3
Compound: 7a
Anticancer activity against human NCI-H1792 cells by HTS assay
Anticancer activity against human NCI-H1792 cells by HTS assay
[PMID: 25139569]
NCI-H1944 IC50
> 50 3
Compound: 7a
Anticancer activity against human NCI-H1944 cells by HTS assay
Anticancer activity against human NCI-H1944 cells by HTS assay
[PMID: 25139569]
MDCK-II IC50
0.57 3
Compound: 12
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry
Inhibition of human BCRP expressed in MDCK2 cells assessed as accumulation of pheophorbide-A preincubated for 30 mins before pheophorbide-A addition measured after 120 mins by flow cytometry
[PMID: 23851114]
NCI-H1792 IC50
>50 3
Compound: 7a
Anticancer activity against human NCI-H1792 cells by HTS assay
Anticancer activity against human NCI-H1792 cells by HTS assay
[PMID: 25139569]
NCI-H1944 IC50
>50 3
Compound: 7a
Anticancer activity against human NCI-H1944 cells by HTS assay
Anticancer activity against human NCI-H1944 cells by HTS assay
[PMID: 25139569]
NCI-H1299 IC50
10.46 3
Compound: 7a
Anticancer activity against human H1299 cells by HTS assay
Anticancer activity against human H1299 cells by HTS assay
[PMID: 25139569]
NCI-H460 IC50
> 50 3
Compound: 7a
Anticancer activity against human H460 cells by HTS assay
Anticancer activity against human H460 cells by HTS assay
[PMID: 25139569]
NCI-H157 IC50
> 50 3
Compound: 7a
Anticancer activity against human NCI-H157 cells by HTS assay
Anticancer activity against human NCI-H157 cells by HTS assay
[PMID: 25139569]
NCI-H460 IC50
>50 3
Compound: 7a
Anticancer activity against human H460 cells by HTS assay
Anticancer activity against human H460 cells by HTS assay
[PMID: 25139569]
NCI-H522 IC50
> 50 3
Compound: 7a
Anticancer activity against human NCI-H522 cells by HTS assay
Anticancer activity against human NCI-H522 cells by HTS assay
[PMID: 25139569]
NCI-H522 IC50
>50 3
Compound: 7a
Anticancer activity against human NCI-H522 cells by HTS assay
Anticancer activity against human NCI-H522 cells by HTS assay
[PMID: 25139569]
NCI-H1792 IC50
> 50 3
Compound: 7a
Anticancer activity against human NCI-H1792 cells by HTS assay
Anticancer activity against human NCI-H1792 cells by HTS assay
[PMID: 25139569]
Neutrophil IC50
1.69 6
Compound: 10
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release
[PMID: 18163582]
NCI-H1944 IC50
> 50 3
Compound: 7a
Anticancer activity against human NCI-H1944 cells by HTS assay
Anticancer activity against human NCI-H1944 cells by HTS assay
[PMID: 25139569]
Neutrophil IC50
1.43 6
Compound: 10
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation
[PMID: 18163582]
NCI-H460 IC50
> 50 3
Compound: 7a
Anticancer activity against human H460 cells by HTS assay
Anticancer activity against human H460 cells by HTS assay
[PMID: 25139569]
NCI-H522 IC50
> 50 3
Compound: 7a
Anticancer activity against human NCI-H522 cells by HTS assay
Anticancer activity against human NCI-H522 cells by HTS assay
[PMID: 25139569]
NCI/ADR-RES IC50
> 100 3
Compound: 3, Pque
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay
Cytotoxicity against human MCF7/ADR cells assessed as cell growth inhibition after 72 hrs by MTT assay
[PMID: 25906385]
Neutrophil IC50
1.43 6
Compound: 10
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced superoxide anion generation
[PMID: 18163582]
Neutrophil IC50
1.69 6
Compound: 10
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release
Antiinflammatory activity in human neutrophils assessed as inhibition of fMet-Leu-Phe/Cytochalasin B-induced elastase release
[PMID: 18163582]
In Vitro

Retusin (20-80 μM; 48 h) reduces the viability of B16F10 mouse melanoma cells to 35.7% (40 μM) and 3.2% (80 μM) of that in the control group, while decreasing the viability of HaCaT human keratinocytes to 99.2% (20 μM) and 40.4% (40 μM) of the control level[1].
Retusin (10 μM; 48 h) reduces α-MSH-induced melanin production to 56.6% of that in the control group and decreases cellular tyrosinase activity to 49.9% of the control level in B16F10 mouse melanoma cells[1].
Retusin (0.1-10 μM; 24 h) considerably increases the percentage of live Neuro-2a cells and decreases the number of early apoptotic cells[2].
Retusin (24-48 h) potently inhibits Aspergillus niger with an MIC of 100 μg/mL; at a concentration of 100 μg/mL, this compound shows no activity against the tested bacteria, other fungi or yeasts[4].
Retusin (0.01-10 μM; 24 h) potently inhibits SARS-CoV-2 replication in Vero E6 cells, with an EC50 of 0.4 μM[5].
Retusin (0.01-10 μM; 48 h) potently inhibits SARS-CoV-2 replication in Calu-3 cells, with an EC50 of 0.6 μM[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: B16F10 murine melanoma cells, HaCaT human keratinocytes
Concentration: 40 μM (B16F10 cells); 80 μM (B16F10 cells); 20 μM (HaCaT cells); 40 μM (HaCaT cells)
Incubation Time: 48 h
Result: Reduced B16F10 cell viability to 35.7% of control at 40 μM and 3.2% of control at 80 μM.
Reduced HaCaT cell viability to 99.2% of control at 20 μM and 40.4% of control at 40 μM.

Apoptosis Analysis[2]

Cell Line: Neuro-2a cells
Concentration: 10 μM
Incubation Time: 24 h
Result: Significantly alleviated the apoptosis damage of Neuro-2a cells induced by 6-OHDA (HY-B1081).
In Vivo

Retusin (10-50 mg/kg; i.p.; single dose) dose-dependently inhibits Copper sulfate (HY-Y1878)-induced emesis in young chicks, with a maximum 45.6% inhibition at 50 mg/kg[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Young male chicks (4 days of age, 25-35 g)[3]
Dosage: 10 mg/kg; 20 mg/kg; 50 mg/kg
Administration: i.p.; single dose
Result: Reduced the mean number of retches to 49.0 (27.4% inhibition vs control).
Reduced the mean number of retches to 48.0 (28.9% inhibition vs control).
Reduced the mean number of retches to 36.7 (45.6% inhibition vs control).
Molecular Weight

358.34

Formula

C19H18O7

CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1C(OC)=C(C2=CC=C(OC)C(OC)=C2)OC3=CC(OC)=CC(O)=C13

Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 25 mg/mL (69.77 mM; ultrasonic and warming and heat to 70°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.7906 mL 13.9532 mL 27.9065 mL
5 mM 0.5581 mL 2.7906 mL 5.5813 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.30%

References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.7906 mL 13.9532 mL 27.9065 mL 69.7661 mL
5 mM 0.5581 mL 2.7906 mL 5.5813 mL 13.9532 mL
10 mM 0.2791 mL 1.3953 mL 2.7906 mL 6.9766 mL
15 mM 0.1860 mL 0.9302 mL 1.8604 mL 4.6511 mL
20 mM 0.1395 mL 0.6977 mL 1.3953 mL 3.4883 mL
25 mM 0.1116 mL 0.5581 mL 1.1163 mL 2.7906 mL
30 mM 0.0930 mL 0.4651 mL 0.9302 mL 2.3255 mL
40 mM 0.0698 mL 0.3488 mL 0.6977 mL 1.7442 mL
50 mM 0.0558 mL 0.2791 mL 0.5581 mL 1.3953 mL
60 mM 0.0465 mL 0.2326 mL 0.4651 mL 1.1628 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Retusin
Cat. No.:
HY-N6829
Quantity:
MCE Japan Authorized Agent: